Intra-cellular Therapies, INC Form 4 insider transactions
Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc., executed stock option exercises and subsequent sales of common stock between August 26 and August 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Intra-Cellular Therapies CEO Sharon Mates Exercises Options and Sells Shares Under 10b5-1 Plan
Sharon Mates, CEO of Intra-Cellular Therapies, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, exercised stock options and sold shares on August 16, 2024.
Executive Vice President and CFO of Intra-Cellular Therapies, Sanjeev Narula, reports the acquisition of stock options and restricted stock units.
Form 4: Intra-Cellular Therapies Director Robert L. Van Nostrand Reports Acquisition of Common Stock
Director Robert L. Van Nostrand of Intra-Cellular Therapies, Inc. reports acquiring 83 shares of common stock at $68.49 per share on June 28, 2024.
Director Rory B. Riggs acquired 262 shares of Intra-Cellular Therapies, Inc. at a price of $68.49 on June 28, 2024, increasing his total holdings to 116,862 shares.
Robert L. Van Nostrand, a director at Intra-Cellular Therapies, Inc., reported the vesting and subsequent disposal of restricted stock units on June 23, 2024.
Director Eduardo Rene Salas exercised 1,567 restricted stock units of Intra-Cellular Therapies, Inc. on June 23, 2024.
Director Joel S. Marcus reports the exercise of restricted stock units and disposition of shares of Intra-Cellular Therapies, Inc.
Director Rory B. Riggs reports exercising stock options and selling shares of Intra-Cellular Therapies, Inc.
Director Robert L. Van Nostrand exercised stock options and sold shares of Intra-Cellular Therapies, Inc. on June 18, 2024, according to a Form 4 filing.
Eduardo Rene Salas, a director at Intra-Cellular Therapies, Inc., was granted stock options and restricted stock units on June 14, 2024.
Form 4: Intra-Cellular Therapies Director Rory B. Riggs Acquires Stock Options and Restricted Stock Units
Director Rory B. Riggs acquired stock options and restricted stock units in Intra-Cellular Therapies, Inc. on June 14, 2024.
Director Joel S. Marcus reports the acquisition of restricted stock units and stock options in Intra-Cellular Therapies, Inc.
Robert L. Van Nostrand, a director at Intra-Cellular Therapies, Inc., reports the acquisition of stock options and restricted stock units.
Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc., reports exercising stock options and changes in beneficial ownership.
Director Robert L. Van Nostrand of Intra-Cellular Therapies, Inc. reports acquiring 79 shares of common stock at $69.20 on March 31, 2024.
Director Rory B. Riggs acquired 260 shares of Intra-Cellular Therapies, Inc. at $69.20 per share on March 31, 2024.
Director Rory B. Riggs exercised options to purchase 20,000 shares of Intra-Cellular Therapies (ITCI) common stock at $18.56 per share on March 20, 2024.
Sharon Mates, the Chairman, President, and CEO of Intra-Cellular Therapies, Inc., sold shares of common stock between March 7 and March 11, 2024, to cover tax liabilities arising from the vesting of restricted stock units.
Lawrence J. Hineline, CFO of Intra-Cellular Therapies, reported the sale of common stock and the exercise of stock options and restricted stock units between March 7 and March 11, 2024.
Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies, Inc., reports the sale of common stock and vesting of restricted stock units.
Mark Neumann, EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc., sold shares of common stock between March 7 and March 11, 2024, to cover tax liabilities arising from the vesting of restricted stock units, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., reports multiple sales of common stock between March 7 and March 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., reports the exercise of stock options resulting in the acquisition and disposal of common stock.
Sharon Mates, Chairman, President, and CEO of Intra-Cellular Therapies, reports the conversion of restricted stock units into common stock.
EVP and General Counsel of Intra-Cellular Therapies, Michael Halstead, reports the conversion of restricted stock units into common stock.
Lawrence J. Hineline, SVP of Finance and CFO at Intra-Cellular Therapies, Inc., reports the conversion of restricted stock units into common stock on March 6, 2024.
EVP and Chief Medical Officer Suresh K. Durgam of Intra-Cellular Therapies, Inc. reports the vesting and conversion of restricted stock units into common stock.
Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies, reports the acquisition of 36,717 restricted stock units on March 1, 2024.